参考文献/References:
[1] Hawa MI,Kolb H,Schloot NC,et al.Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype:Action LADA 7[J] .Diabetes Care,2013,36（4）：908-913.
[2] Sumpter KM,Adhikari S,Grishman EK,et al.Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes[J].Pediatr Diabetes,2011,12（7）：656-667.
[3] Moran A,Bundy B,Becker DJ,et al.Interleukin-1 antagonism in type 1 diabetes of recent onset：two multicentre,randomised,double：blind,placebo：controlled trials[J].Lancet,2013,381（9881）：
1905-1915.
[4] Herold KC,Gitelman SE,Willi SM,et al.Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period： a randomised controlled trial[J].Diabetologia,2013,56（2）：391-400.
[5] Lebastchi J,Deng S,Lebastchi AH,et al.Immune therapy and β-cell death in type 1 diabetes[J].Diabetes,2013,62（5）：1676-1680.
[6] Sherry N,Hagopian W,Ludvigsson J,et al.Teplizumab for treat-ment of type 1 diabetes（Protégé study）：1-year results from a randomised,placebocontrolled trial[J].Lancet,2011,378（9790）：487-497.
[7] Zanin-Zhorov A,Tal G,Shivtiel S,et al.Heat shock protein 60 activates cytokine-associated negative regulator suppressor of cytokine signaling 3 in T cells：effects on signaling,chemotaxis,and inflammation[J].J Immunol,2005,175（1）：276-285.
[8] Quintana FJ,Cohen IR.The HSP60 immune system network[J]. Trends Immunol,2011,32（2）：89-95.
[9] Raz I,Avron A,Tamir M,et al.Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function：extension of a randomized,double-blind,phase Ⅱ trial[J].Diabetes Metab Res Rev,2007,23（4）：292-298.
[10] Abulafia-Lapid R,Elias D,Raz I,et al.T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides[J].J Autoimmun,1999,12（2）：121-129.
[11] Raz I,Elias D,Avron A,et al.Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide （DiaPep277）：a randomised,double-blind,phase Ⅱ trial[J].Lancet,2001,358（9295）：1749-1753.
[12] Huurman VA,van der Meide PE,Duinkerken G,et al.Immuno-logical efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes[J].Clin Exp Immunol,2008,152（3）：488-497.
[13] Buzzetti R,Cernea S,Petrone A,et al.C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277：an exploratory study[J].Diabetes,2011,60（11）：3067-3072.
[14] Lazar L,Ofan R,Weintrob N,et al.Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes：a randomised,double-blind phase Ⅱ study[J].Diabetes Metab Res Rev,2007,23（4）：286-291.
[15] Schloot NC,Meierhoff G,Lengyel C,et al.Effect of heat shock protein peptide DiaPep277 on β-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1：two prospective,randomized,double-blind phase Ⅱ trials[J].Diabetes Metab Res Rev,2007,23（4）：276-285.
[16] Tuccinardi D,Fioriti E,Manfrini S,et al.DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes[J].Expert Opin Biol Ther,2011,11（9）：1233-1240.
[17] Pozzilli P,Visalli N,Buzzetti R,et al.Metabolic and immune parameters at clinical onset of insulin-dependent diabetes：a population-based study.IMDIAB Study Group.Immunotherapy Diabetes[J]. Metabolism,1998；47（10）：1205-1210.